UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2024
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published
one announcement (the “Public Notices”) to the Australian Securities Exchange on July 9, 2024 titled:
| - | “Immuron CEO Steven Lydeamore to presentation at Sharewise” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
IMMURON LIMITED |
|
|
|
Date: July 9, 2024 |
By: |
/s/ Phillip Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_001.jpg)
Immuron
CEO, Steven Lydeamore to present at Sharewise
Melbourne, Australia, July 9, 2024:
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our
Chief Executive Officer, Steven Lydeamore will be presenting at Sharewise on Tuesday 9 July 2024, 11:00am AEST.
A copy of the presentation being made
is included below.
This release has been authorised by the
directors of Immuron Limited.
- - - END - - -
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ:
IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies
for the treatment of infectious diseases.
About Travelan®
Travelan®
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a
highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan®
is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’
Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed
natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan®
is sold as a dietary supplement for digestive tract protection.
Travelers’ diarrhea (TD)
TD is generally defined as the passage
of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus
in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung
et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions
(Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected
given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious
disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and
Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).
Immuron Platform Technology
Immuron’s proprietary technology
is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing
highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment
of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses
this unique ability to remain active in the human GI tract delivering its full benefits
directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines
across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal
tract and neutralize the toxins they produce.
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_002.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_003.jpg)
IMM-124E (Travelan®)
IMM-124E was developed using Immuron’s
platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine
containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels
of antibodies against selected surface antigens from the most common strains of ETEC.
The resultant hyperimmune colostrum
IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin
(Sears et al., 2017).
The antibodies produced in IMM-124E
have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range
of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core ‘R’ region of LPS
from the 13 serotypes used in the ETEC vaccine.
IMM-124E is manufactured
into a tablet form referred to as Travelan®.
IMM-529
Immuron is developing IMM-529 as an adjunctive therapy
in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI).
IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment
of normal gut flora, providing an attractive oral preventative for recurrent CDI.
Immuron is collaborating with Dr. Dena Lyras and her team
at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate
hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin
B (TcB), the spores and the surface layer proteins of the vegetative cells.
This unique 3-target approach has yielded promising results
in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence
(67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with
whole cell lysates of many different human strains of C. diff including hypervirulent strains.
To our knowledge, IMM-529 is, to date, the only investigational
drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).
References
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea
during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.
Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine
antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017).
https://doi.org/10.1038/s41598-017-03982-5
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea.
Adv Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T
and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused
by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862– 868; 2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble
DR. Incidence, etiology, and impact of diarrhea among long-term travelers’ (US military and similar populations): A systematic review.
American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_002.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_003.jpg)
Sears KT, Tennant SM, Reymann MK,
Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic
Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.
Steffen R. Epidemiology of travelers'
diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/
and https://www.travelan.com
Subscribe for Immuron News: Here
FORWARD-LOOKING STATEMENTS:
This press release may contain
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy
and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks
relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships;
risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate
and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any
change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required
by law.
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_004.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_005.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_006.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_007.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_008.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_009.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_010.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_011.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_012.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_013.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_014.jpg)
![](https://www.sec.gov/Archives/edgar/data/1660046/000121390024059911/ex99-1_015.jpg)
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 7 2024 まで 8 2024
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 8 2023 まで 8 2024